Suppr超能文献

受伤前使用华法林的患病率及影响:对国家创伤数据库的分析

Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank.

作者信息

Dossett Lesly A, Riesel Johanna N, Griffin Marie R, Cotton Bryan A

机构信息

Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

出版信息

Arch Surg. 2011 May;146(5):565-70. doi: 10.1001/archsurg.2010.313. Epub 2011 Jan 17.

Abstract

OBJECTIVES

To describe the prevalence of preinjury warfarin use in a large national sample of trauma patients and to define the relationship between preinjury warfarin use and mortality.

DESIGN

Retrospective cohort study.

SETTING

The National Trauma Databank (7.1).

PATIENTS

All patients admitted to eligible trauma centers during the study period; 1,230,422 patients (36,270 warfarin users) from 402 centers were eligible for analysis.

MAIN OUTCOME MEASURES

Prevalence of warfarin use and all-cause in-hospital mortality. Multivariate logistic regression was used to estimate the odds ratio (OR) for mortality associated with preinjury warfarin use.

RESULTS

Warfarin use increased among all patients from 2.3% in 2002 to 4.0% in 2006 (P < .001), and in patients older than 65 years, use increased from 7.3% in 2002 to 12.8% in 2006 (P < .001). Among all patients, 9.3% of warfarin users died compared with only 4.8% of nonusers (OR, 2.02; 95% confidence interval [CI], 1.95-2.10; P < .001). After adjusting for important covariates, warfarin use was associated with increased mortality among all patients (OR, 1.72; 95% CI, 1.63-1.81; P < .001) and patients 65 years and older (OR, 1.38; 95% CI, 1.30-1.47; P < .001).

CONCLUSIONS

Warfarin use is common among injured patients and its prevalence has increased each year since 2002. Its use is a powerful marker of mortality risk, and even after adjusting for confounding comorbidities, it is associated with a significant increase in death.

摘要

目的

描述在一个大型全国性创伤患者样本中受伤前使用华法林的情况,并确定受伤前使用华法林与死亡率之间的关系。

设计

回顾性队列研究。

地点

国家创伤数据库(7.1)。

患者

研究期间所有入住符合条件的创伤中心的患者;来自402个中心的1,230,422名患者(36,270名华法林使用者)符合分析条件。

主要观察指标

华法林使用情况及全因院内死亡率。采用多因素logistic回归估计受伤前使用华法林与死亡率相关的比值比(OR)。

结果

所有患者中,华法林的使用从2002年的2.3%增至2006年的4.0%(P <.001),65岁及以上患者中,其使用从2002年的7.3%增至2006年的12.8%(P <.001)。在所有患者中,9.3%的华法林使用者死亡,而非使用者仅为4.8%(OR,2.02;95%置信区间[CI],1.95 - 2.10;P <.001)。在对重要协变量进行调整后,华法林使用与所有患者死亡率增加相关(OR,1.72;95%CI,1.63 - 1.81;P <.001),在65岁及以上患者中也是如此(OR,1.38;95%CI,1.30 - 1.47;P <.001)。

结论

华法林在受伤患者中使用普遍,自2002年以来其使用率逐年上升。其使用是死亡风险的有力标志物,即使在对混杂的合并症进行调整后,仍与死亡显著增加相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验